Open Label Phase I Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia (With Pilot Feasibility Study in Combination With Pegylated Interferon Alfa 2a for Patients Who do Not Respond to the Single Agent at Each Dose Level)

Trial Profile

Open Label Phase I Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia (With Pilot Feasibility Study in Combination With Pegylated Interferon Alfa 2a for Patients Who do Not Respond to the Single Agent at Each Dose Level)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Jun 2018

At a glance

  • Drugs Idasanutlin (Primary) ; Peginterferon alfa-2a
  • Indications Essential thrombocythaemia; Polycythaemia vera
  • Focus Adverse reactions
  • Most Recent Events

    • 08 Jun 2018 Planned End Date changed from 1 Apr 2018 to 1 Dec 2019.
    • 08 Jun 2018 Planned primary completion date changed from 1 Apr 2017 to 1 Dec 2019.
    • 08 Jun 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top